Merus
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
MRUS Key Statistics
MRUS News
Merus N.V. MRUS shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in...
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Friday. Shares of Frontline plc FRO rose during Friday's session following first-...
Merus (MRUS) stock soared on Friday after the clinical-stage oncology company released interim results from its ongoing Phase 2 trial of the bispecific antibody...
Analyst ratings
100%
of 18 ratingsMore MRUS News
BMO Capital analyst Etzer Darout raised the firm’s price target on Merus (MRUS) to $110 from $96 and keeps an Outperform rating on the shares. The firm notes th...
Merus (MRUS) N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab...
Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly These names in...
Analyst John Newman from Canaccord Genuity maintained a Buy rating on Merus (MRUS – Research Report) and keeping the price target at $67.00. Confident Investin...